title: Results of the MRI substudy of the intravenous magnesium efficacy in stroke trial.
abstract: OBJECTIVE
  Although magnesium is neuroprotective in animal stroke models, no clinical benefit was confirmed in the Intravenous Magnesium Efficacy in Stroke (IMAGES) trial of acute stroke patients. The Magnetic Resonance in IMAGES (MR IMAGES) substudy investigated the effects of magnesium on the imaging surrogate outcome of infarct growth.
  
  
  METHODS
  IMAGES trial patients in participating centers were randomized to receive either intravenous magnesium or placebo within 12 hours of stroke onset. Infarct growth was defined as volume difference between baseline diffusion-weighted imaging and day 90 fluid-attenuated inversion recovery image lesions. Patients who died were imputed the largest infarct growth observed.
  
  
  RESULTS
  Among the 90 patients included in the primary analysis, there was no difference in infarct growth (median absolute growth, P=0.639; median percentage growth, P=0.616; proportion with any growth, P=0.212) between the 46 treated with magnesium and 44 with placebo. Infarct growth correlated with NIHSS score change from baseline to day 90. There was a trend showing baseline serum glucose correlated with infarct growth with magnesium treatment, but not in the placebo group. The mismatch frequency was reduced from 73% to 47% by increasing the mismatch threshold from >20% to >100% of core volume.
  
  
  CONCLUSIONS
  Infarct growth, confirmed here as a surrogate for clinical progression, was similar between magnesium and placebo treatment, paralleling the main IMAGES trial clinical outcomes. Glucose was a covariate for infarct growth with magnesium treatment. A more stringent mismatch threshold to define penumbra more appropriately would have excluded half of the patients in this 12-hour time window stroke study.
authors.affiliation: Georgetown University, Washington, DC 20007, USA. ck256@georgetown.edu
authors.forename: Chelsea S
authors.initials: CS
authors.lastname: Kidwell
authors.forename: Kennedy R
authors.initials: KR
authors.lastname: Lees
authors.forename: Keith W
authors.initials: KW
authors.lastname: Muir
authors.forename: Christopher
authors.initials: C
authors.lastname: Chen
authors.forename: Stephen M
authors.initials: SM
authors.lastname: Davis
authors.forename: Deidre A
authors.initials: DA
authors.lastname: De Silva
authors.forename: Christopher J
authors.initials: CJ
authors.lastname: Weir
authors.forename: Sidney
authors.initials: S
authors.lastname: Starkman
authors.forename: Jeffry R
authors.initials: JR
authors.lastname: Alger
authors.forename: Jeffrey L
authors.initials: JL
authors.lastname: Saver
mesh_terms: D000208:Acute Disease; D000368:Aged; D000704:Analysis of Variance; D001786:Blood Glucose / Q000378:metabolism; D002544:Cerebral Infarction / Q000150:complications / Q000188:drug therapy / Q000473:pathology; D038524:Diffusion Magnetic Resonance Imaging; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007091:Image Processing, Computer-Assisted; D007275:Injections, Intravenous; D008278:Magnesium Sulfate / Q000008:administration & dosage / Q000627:therapeutic use*; D008279:Magnetic Resonance Imaging; D008297:Male; D018696:Neuroprotective Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D018579:Patient Selection; D020521:Stroke / Q000188:drug therapy* / Q000473:pathology*; D016896:Treatment Outcome
chemical_list: D001786:Blood Glucose; D018696:Neuroprotective Agents; D008278:Magnesium Sulfate